Supernus Pharm (SUPN)

$SUPN: Current market context shows a strong upward momentum with the last close at $47.26. The RSI at 61.67 indicates bullish sentiment, but not overbought, allowing for further upside potential. The MA30 at $46.98 supports a positive trend, while the MA50 at $48.3 suggests resistance around this level. The 60D high of $57.65 provides a clear target for profit-taking. Actionable Trade Alert: - Suggested Entry: $47.50 - Stop Loss: $45.50 (1.76% below entry) - Take Profit Targets: 1. $50.00 (5.26% ROI) 2. $53.00 (11.84% ROI) 3. $55.50 (16.84% ROI) With the potential for a 16.84% ROI at TP3, this trade aligns well with the current market dynamics. Monitor RSI and MA levels closely for any shifts in momentum. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com

$SUPN Current Stock Price: $46.55 Contracts to trade: $45 SUPN Dec 19 2025 Call Entry: $1.25 Exit: $2.19 ROI: 75% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

$SUPN Actionable Trade Alert: Market Context: $SUPN is currently trading at $45.42, positioned between its 60-day high of $57.65 and low of $43.11. The RSI at 52.49 indicates a neutral stance, suggesting potential for upward movement without being overbought. Directional Bias: The stock is below both the 30-day MA (47.5) and 50-day MA (48.35), indicating a bearish trend in the short term. However, the proximity to the 60-day low suggests a possible reversal opportunity. Trade Plan: - Suggested Entry: $45.50 (slightly above the last close to confirm upward momentum) - Stop Loss: $43.00 (below the 60-day low for risk management) - Take Profit Targets: 1. Target 1: $48.00 (5.5% ROI) 2. Target 2: $51.00 (12.3% ROI) 3. Target 3: $53.00 (16.7% ROI) This strategy offers a solid risk-reward ratio, with a potential 17% ROI on the third target. Monitor market conditions closely for adjustments. https://privateprofiteers.com

$SUPN: Current market context shows a recent close at $46.55, with an RSI of 58.82 indicating bullish momentum but not overbought. The price is below both the 30-day MA of $47.72 and the 50-day MA of $48.38, suggesting potential resistance ahead. However, the stock is trading closer to the 60-day high of $57.65, indicating room for upward movement within the high-low range of $43.11 to $57.65. Actionable Trade Plan: - Suggested Entry: $46.55 - Stop Loss: $44.00 (approximately 5.5% below entry) - Take Profit Targets: 1. $50.00 (7.5% ROI) 2. $53.00 (13.3% ROI) 3. $54.50 (17.0% ROI) The bullish bias is supported by the RSI and proximity to the 60-day high, while the ATR of $1.29 indicates manageable volatility. Monitor for price action around targets for potential adjustments. https://privateprofiteers.com

Actionable Trade Alert for $SUPN: Market Context: $SUPN closed at $45.1, showing a moderate RSI of 54.41, indicating neutral momentum. The stock is currently trading between its 60D high of $57.65 and low of $43.11, suggesting potential for upward movement. Directional Bias: With the current price below both the 30-day MA (48.14) and 50-day MA (48.42), there is a bearish bias. However, the RSI indicates room for upward movement, and the stock is near the lower end of its recent range, which could favor a rebound. Trade Plan: - Suggested Entry: $45.5 (above last close to confirm upward momentum) - Stop Loss: $43.0 (below 60D low for risk management) - Take Profit Targets: 1. $48.0 (1st target, approx. 5.5% ROI) 2. $50.0 (2nd target, approx. 9.9% ROI) 3. $52.5 (3rd target, approx. 16.5% ROI) This plan aims for at least a 17% ROI on the final target while managing risk effectively. https://privateprofiteers.com

Actionable Trade Alert for $SUPN: Market Context: $SUPN closed at $45.1, showing a moderate RSI of 54.41, indicating neutral momentum. The stock is currently trading between its 60D high of $57.65 and low of $43.11, suggesting potential for upward movement. Directional Bias: With the current price below both the 30-day MA (48.14) and 50-day MA (48.42), there is a bearish bias. However, the RSI indicates room for upward movement, and the stock is near the lower end of its recent range, which could favor a rebound. Trade Plan: - Suggested Entry: $45.5 (above last close to confirm upward momentum) - Stop Loss: $43.0 (below 60D low for risk management) - Take Profit Targets: 1. $48.0 (1st target, approx. 5.5% ROI) 2. $50.0 (2nd target, approx. 9.9% ROI) 3. $52.5 (3rd target, approx. 16.5% ROI) This plan aims for at least a 17% ROI on the final target while managing risk effectively. https://privateprofiteers.com

$SUIG $SUPN $SUPV $SVRA $SWKS proven Accuracy

$SUPN 🚀🚀🚀🚀🚀🚀

$SUIG $SUPN $SUPV $SVRA $SWKS 🔥

🚀 $SUPN Token (Superp) Analysis! 🚀 ✨ Innovative Trading: SUP fuels Superp, a DEX offering "No Liquidation" high-leverage trading for volatile assets like meme coins. Imagine a trading safety net, reducing abrupt losses! 🗳️ Community Power: Holding SUP gives you a voice in platform governance, letting you shape its future like a shareholder, plus staking rewards. 📈 Growing Ecosystem: With $37B+ volume (Q3 2025), and plans for Solana expansion, Superp is expanding its reach. ⚠️ Supply Dynamics: A large portion of SUP's 1B tokens are still locked, so future unlocks could create selling pressure. #Crypto #DeFi #Superp

$SUPN Share Price: $46.14 Contract Selected: Jun 18, 2026 $50 Calls Buy Zone: $2.12 – $2.62 Target Zone: $3.39 – $4.14 Potential Upside: 51% ROI Time to Expiration: 218 Days | Updates via https://fxcapta.com/stockinfo/

$CING Anyone else think $80 may actually be in line if they get PUFDA or im I just an idiot? $CING already has patents in these countries: Australia, Canada, Israel, and Europe. Add pending US, Korea and Hong Kong and your looking at a nice market share lock. $SUPN $AXSM have mc over $1B and I think $CING could hit that as well once given pufda. Interested to hear everyone's thoughts for long term

$SUPN - Supernus Pharmaceuticals Inc. Common Stock - 10Q - Updated Risk Factors SUPN updates tariff risk to focus on newly announced tariffs for pharmaceuticals, drops risks tied to 2025 drug pricing Executive Orders, and adds new warnings about costly, distracting legal actions. #Pharmaceuticals #RegulatoryChanges #LegalRisk #DrugPricing #TariffRisk 🟢 Added 🟠 Removed https://d-risk.ai/SUPN/10-Q/2025-11-06

$SUPN Lots of profit taking going on here on a quarter where they took some one-time charges that impacted bottom line, but actually improved guidance for the year. Big yellow flag was actually that they are having supply issues due to the success of one of their newer products. They need to get that resolved quickly so that revenue growth can continue.

$SUPN Supernus reports Q3 EPS (80c) vs. 69c last year -- Q3 revenue $192.1M, consensus $180.22M. -- Raises FY25 revenue view to $685M-$705M from $670M-$700M, consensus $702.59M. -- Raises FY25 adjusted operating earnings view to $125M-$145M from $105M-$135M.

$SUPN https://ir.supernus.com/news-releases/news-release-details/supernus-announces-third-quarter-2025-financial-results

$SUPN thing about it getting $LGND ary wen $XBI is in $RYTM 🐒🍌🧠⏰♾️

$SUPN "Heads up alert! Only three days until Upcoming earnings on Tuesday, 11/4/2025 for $SUPN Bullish (7.5) Supernus Pharmaceuticals (SUPN) is currently positioned as a strong contender in the specialty pharmaceuticals sector, particularly within the central nervous system (CNS) treatment space. The company has exhibited remarkable stock performance, with a one-year total shareholder return of approximately 54%, and a notable 55% increase over the past three months alone. This momentum is largely attributed to robust sales growth from its key products, Qelbree and GOCOVRI, which have been instrumental in exceeding revenue expectations. The company’s P/E ratio stands at a competitive level compared to its peers, reflecting its growth potential and operational efficiency. Moreover, analysts have noted a positive earnings surprise history for SUPN, which bodes well for future performance. The latest earnings forecast suggests a slight decline in earnings, yet this has not dampened investor sentiment, as evidenced by recent upgrades from financial analysts, including a shift from ""Neutral"" to ""Overweight"" by Piper Sandler. In terms of upcoming earnings reports, Supernus Pharmaceuticals is set to announce its third-quarter financial results on November 4, 2025. Analysts are cautiously optimistic, anticipating a decline in earnings but maintaining a focus on the company’s ability to leverage its CNS drug pipeline effectively. Historical performance indicates that SUPN has often surpassed earnings estimates, which could play a significant role in shaping market expectations. Consensus estimates suggest a slight contraction in earnings, yet the strong sales trajectory of its flagship products may mitigate the impact of this anticipated decline. Investors are particularly keen on how management addresses growth strategies and responds to market dynamics during the earnings call. Overall, the specialty pharmaceuticals sector has shown resilience and growth potential, bolstered by innovative product pipelines and increasing demand for CNS-related treatments. This sector's performance has been strong, with many companies, including Supernus, capitalizing on emerging trends and shifting consumer needs. As such, SUPN's positioning within this landscape, coupled with its operational strengths, suggests a favorable outlook for investors. - Funds were net buyers of $SUPN during the previous reporting quarter. - Funds with large holdings in $SUPN include: - Armistice Capital LLC, MV: $152MM. Fund Rank: 72% www.armisticecapital.com - GW&K Investment Management LLC, MV: $40MM. Fund Rank: 76% - Rubric Capital Management LP, MV: $22MM. New position. Fund Rank: 92% www.rubriccapital.com - Point72 Asset Management LP, MV: $16MM. Fund Rank: 91% www.point72.com - Krensavage Asset Management LLC, MV: $15MM. Fund Rank: 65% www.krensavage.com - Last 10 days performance: 9% - Last 30 days performance: 15% - Last 90 days performance: 55% Some of the latest news articles: - Title: Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for Publication Date: 10/30/2025 2:00:28 PM, Source: yahoo URL: https://finance.yahoo.com/news/analysts-estimate-amphastar-pharmaceuticals-amph-140028727.html?.tsrc=rss - Title: 3 Cash-Producing Stocks That Fall Short Publication Date: 10/30/2025 4:32:31 AM, Source: yahoo URL: https://finance.yahoo.com/news/3-cash-producing-stocks-fall-043231382.html?.tsrc=rss - Title: BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue Estimates Publication Date: 10/29/2025 9:15:01 PM, Source: yahoo URL: https://finance.yahoo.com/news/bridgebio-pharma-bbio-reports-q3-211501816.html?.tsrc=rss - Title: Can Supernus Pharmaceuticals Sustain Momentum After 13% Jump on Neuroscience Pipeline News? Publication Date: 10/29/2025 5:54:40 PM, Source: yahoo URL: https://finance.yahoo.com/news/supernus-pharmaceuticals-sustain-momentum-13-175440241.html?.tsrc=rss Follow us on stocktwits.com for more earnings alerts. Not a financial advice. Not a trading signal."

$SUPN Opportunity TD Cowen raises target price to $60 from $45

TD Cowen has adjusted their stance on Supernus Pharmaceuticals ( $SUPN ), setting the rating to Buy with a target price of 45 → 60.

Piper Sandler upgrades $SUPN to Overweight and raises its price target to $65 from $40. The boost is driven by excitement over its new Onapgo pump for Parkinson's disease, seen as a major profit driver. 💊

Piper Sandler has updated their rating for Supernus Pharmaceuticals ( $SUPN ) to Overweight with a price target of 65.